Optimisation of mammographic breast cancer screening using a computer simulation model.

To optimise breast cancer screening protocols, risk (induction of fatal tumors) versus benefit (reduction in the number of fatal tumors) analyses are performed for a simulated stable Swedish female population, using the Model for evaluation of Breast cancer Screening (MBS). The present study comprises, the influences of various screening parameters, i.e. ages at which screening is started and stopped, interval period between successive sessions, tumor detection limits for screening and average glandular dose per screening session. When the results of the present study are expressed in terms of numbers of fatal breast tumors, it appears that starting and stopping ages for screening of 40 and 80 years, respectively, seem realistic. An increased screening frequency results in a larger reduction of breast cancer mortality. This reduction is significant for ages between 40 and 51 years but only marginal for ages above 70 years. High resolution screening, i.e., the detection of tumors at smaller size, results in a larger benefit but does not indicate a younger age for starting of screening. The average glandular dose per screening session does only influence the risks of screening. As separate risk and benefit results are presented, a change in average glandular dose on the total effect of screening can easily be calculated.

[1]  N. Day Screening for breast cancer. , 1991, British medical bulletin.

[2]  L. Tabár,et al.  Breast screening, prognostic factors and survival--results from the Swedish two county study. , 1991, British Journal of Cancer.

[3]  Roland Holland,et al.  Age‐dependent growth rate of primary breast cancer , 1993, Cancer.

[4]  D. Brenner,et al.  Enhanced risk from low-energy screen--film mammography X rays. , 1989, The British journal of radiology.

[5]  B Lundgren,et al.  Observations on growth rate of breast carcinomas and its possible implications for lead time , 1977, Cancer.

[6]  H A Risch,et al.  Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. , 1989, The New England journal of medicine.

[7]  M Tubiana,et al.  Relation between the pathological nature and the growth rate of human tumors. , 1971, European journal of cancer.

[8]  J. Zoetelief,et al.  MBS: a model for risk benefit analysis of breast cancer screening. , 1995, The British journal of radiology.

[9]  J. Spratt,et al.  Rate of growth of soft tissue metastases of breast cancer , 1972, Cancer.

[10]  A. Pearlman Breast cancfr–‐influence of growth rate on prognosis and treatment evaluation. A study based on mastectomy scar recurrences , 1976, Cancer.

[11]  L. Tabár,et al.  Breast cancer treatment and natural history: new insights from results of screening , 1992, The Lancet.

[12]  R Holland,et al.  The occurrence of interval cancers in the Nijmegen screening programme. , 1989, British Journal of Cancer.

[13]  D. Fournier,et al.  Growth rate of 147 mammary carcinomas , 1980, Cancer.

[14]  J. Spratt,et al.  Growth rates of primary breast cancers , 1979, Cancer.

[15]  Bengt Lundgren,et al.  Breast carcinoma growth rate described by mammographic doubling time and S‐phase fraction. Correlations to clinical and histopathologic factors in a screened population , 1992, Cancer.

[16]  F R Watson,et al.  The gross rates of growth of human mammary carcinoma , 1972, Cancer.

[17]  T. Landberg,et al.  Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. , 1988, BMJ.